Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non—small cell lung cancer (NSCLC).

The FLAURA trial is investigating osimertinib (Tagrisso) versus standard of care in the frontline setting. The primary endpoint of this study is progression-free survival (PFS). The FLAURA trial has shown an improvement of PFS with 18.6 months.

It has also been discovered the osimertinib is a good regimen for CNS metastases, states Peters. Additionally, there was a beneficial toxicity profile for the patients who received osimertinib. According to Peters, osimertinib is the new standard of care for patient with EGFR-mutated NSCLC.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ESMO Congress

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non

Dr. Peters Discusses the FLAURA Trial for EGFR-Mutated NSCLC